Home > Insider Trading > Filing (0001140361-13-045902)

Filing Details

Accession Number:: 0001140361-13-045902
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-12-12 17:26:26
Reporting Period:: 2013-12-10

Filing Date:: 2013-12-12
Accepted Time:: 2013-12-12 17:26:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1031927	Echo Therapeutics Inc.	ECTE	Electromedical & Electrotherapeutic Apparatus (3845)	411649949

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1120642	Uri Landesman	C/O Platinum Management (Ny) Llc 152 West 57Th Street, 4Th Floor New York NY 10019	No	No	Yes	No
1299265	Platinum Partners Value Arbitrage Fund, Lp	C/O Walkers Corporate Services Limited Walker House, 87 Mary Street Georgetown, Grand Cayman E9 KY1-9002	No	No	Yes	No
1339643	Mark Nordlicht	C/O Platinum Management (Ny) Llc 152 West 57Th Street, 4Th Floor New York NY 10019	No	No	Yes	No
1368616	Platinum Management (Ny) Llc	152 West 57Th Street New York NY 10019	No	No	Yes	No
1404598	Platinum-Montaur Life Sciences, Llc	152 West 57Th Street 54Th Floor New York NY 10019	No	No	Yes	No
1413041	Platinum Long Term Growth Vii, Llc	152 West 57Th Street 54Th Floor New York NY 10019	No	No	Yes	No
1476165	L.p. Fund Master Opportunity Liquid Partners Platinum	152 West 57 Street, 4Th Floor New York NY 10019	No	No	Yes	No
1582140	Platinum Liquid Opportunity Management (Ny) Llc	152 West 57Th Street 4Th Floor New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-12-10	55,655	$2.75	507,824	No	4	P	Indirect	By Platinum Partners Value Arbitrage Fund L.P.
Common Stock	Acquisiton	2013-12-10	13,914	$2.75	578,452	No	4	P	Indirect	By Platinum Partners Liquid Opportunity Master Fund L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Platinum Partners Value Arbitrage Fund L.P.
No	4	P	Indirect	By Platinum Partners Liquid Opportunity Master Fund L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series E Preferred Stock	Acquisiton	2013-12-10	1,398,890	$2.75	1,398,890	$0.00
Common Stock	Series E Preferred Stock	Acquisiton	2013-12-10	349,723	$2.75	349,723	$0.00
Common Stock	Warrants	Acquisiton	2013-12-10	1	$0.00	145,455	$2.75
Common Stock	Warrants	Acquisiton	2013-12-10	1	$0.00	36,363	$2.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,398,890			No	4	P	Indirect
349,723			No	4	P	Indirect
1	2014-06-11	2018-12-10	No	4	P	Indirect
1	2014-06-11	2018-12-10	No	4	P	Indirect

Footnotes

This Form 4 is filed jointly by Platinum Partners Value Arbitrage Fund L.P. ("PPVA"), Platinum Partners Liquid Opportunity Master Fund L.P. ("PPLO"), Platinum Long Term Growth VII, LLC ("Platinum VII"), Platinum-Montaur Life Sciences, LLC ("Platinum-Montaur"), Platinum Management (NY) LLC ("Platinum Management"), Platinum Liquid Opportunity Management (NY) LLC ("Platinum Liquid Management"), Mark Nordlicht and Uri Landesman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
Securities owned directly by PPVA. Each of Platinum Management, as the Investment Manager of PPVA, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Management, may be deemed to beneficially own the securities owned directly by PPVA.
Securities owned directly by PPLO. Each of Platinum Liquid Management, as the Investment Manager of PPLO and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Liquid Management, may be deemed to beneficially own the securities owned directly by PPLO.
The shares of Series E Preferred Stock (the "Preferred Stock") are immediately exercisable. Pursuant to the terms of the Preferred Stock, the number of shares of Common Stock that the Preferred Stock can be converted into is limited, pursuant to the terms of the Preferred Stock, to the number of shares of Common Stock to be issued pursuant to such conversion that would not exceed, when aggregated with all other shares of Common Stock owned by the holder at such time (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder ("Section 13(d)")) 19.99% of all of the Common Stock outstanding at such time (the "19.99% Preferred Stock Blocker").
The 19.99% Preferred Stock Blocker may be waived only upon (A) the holder providing the Issuer with 61 days' notice that the holder would like to waive the 19.99% Preferred Stock Blocker and (B) the stockholders of the Issuer approving the waiver of the 19.99% Preferred Stock Blocker, with regard to any or all shares of Common Stock issuable upon conversion of the Preferred Stock.
The Preferred Stock also contains restrictions on conversion such that the holder may not convert the Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by the holder at such time (as determined in accordance with Section 13(d)), in excess of 9.99% of all of the Common Stock outstanding at such time (the "9.99% Preferred Stock Blocker"). The 9.99% Preferred Stock Blocker may be waived upon the holder providing the Issuer with 61 days' notice that such holder would like to waive the 9.99% Preferred Stock Blocker.
Pursuant to the terms of the Warrants, the Warrants may not be exercised if the exercise would result in the holder beneficially owning (as determined in accordance with Section 13(d)) in excess of 19.99% of all of the Common Stock outstanding at such time (the "19.99% Warrant Blocker"). The 19.99% Warrant Blocker may be waived only upon (A) the holder providing the Issuer with 61 days' notice that the holder would like to waive the 19.99% Warrant Blocker and (B) the stockholders of the Issuer approving the waiver of the 19.99% Warrant Blocker, with regard to any or all shares of Common Stock issuable upon exercise of the Warrant.
Pursuant to the terms of the Warrants, the Warrants may not be exercised if the exercise would result in the holder beneficially owning (as determined in accordance with Section 13(d)) in excess of 9.99% of all of the Common Stock outstanding at such time (the "9.99% Warrant Blocker"). The 9.99% Warrant Blocker may be waived upon the holder providing the Issuer with 61 days' notice that such holder would like to waive the 9.99% Warrant Blocker.